{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:44:18Z","timestamp":1792651458956,"version":"4.5.0"},"reference-count":26,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"\n BACKGROUND AND OBJECTIVES<\/jats:title>\n Disease caused by Streptococcus pneumoniae is associated with considerable morbidity and mortality in children. Pneumococcal conjugate vaccines (PCVs) are well tolerated and effective at reducing pneumococcal disease caused by vaccine serotypes. VAXNEUVANCE (V114) is a 15-valent PCV containing 13 serotypes in Prevnar 13 (PCV13), plus serotypes 22F and 33F. This large phase 3 study evaluated safety and tolerability of V114 in infants.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n In total, 2409 infants were randomized to receive V114 or PCV13 at 2, 4, 6, and 12 to 15 months of age. Safety was evaluated as the proportion of participants with adverse events (AEs). Solicited and unsolicited injection-site and systemic AEs were collected for 14 days after each study vaccination, and serious AEs up to 6 months after the last PCV dose.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n The proportions of participants with injection-site, systemic, vaccine-related, and serious AEs were generally comparable between recipients of V114 and PCV13. The most frequently reported AEs were solicited, with irritability and somnolence being the most frequent in both groups. Although the incidence of some AEs was higher in the V114 group, the between-group differences were small. The majority of experienced AEs were of mild-to-moderate intensity and lasted \u22643 days. There were 2 vaccine-related serious AEs of pyrexia in the V114 group, and 2 nonvaccine-related deaths, 1 in each group. No participant discontinued study vaccine because of AEs.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n V114 is well tolerated and has a generally comparable safety profile to that of PCV13. These study results support routine use of V114 in infants.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2022-060428","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T08:13:36Z","timestamp":1686644016000},"source":"Crossref","is-referenced-by-count":11,"title":["Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study"],"prefix":"10.1542","volume":"152","author":[{"given":"Natalie","family":"Banniettis","sequence":"first","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Horn","sequence":"additional","affiliation":[{"name":"bPediatric Office Dr. Horn, Schoenau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[{"name":"cUniversity of British Columbia and BC Children\u2019s Hospital Research Institute, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrita M.","family":"Patel","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greenberg","sequence":"additional","affiliation":[{"name":"dSoroka Medical Center, Research, Beersheba, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peninnah","family":"Oberdorfer","sequence":"additional","affiliation":[{"name":"eChiang Mai University, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[{"name":"fKaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rupp","sequence":"additional","affiliation":[{"name":"gUniversity of Texas Medical Branch, Galveston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Dagan","sequence":"additional","affiliation":[{"name":"hThe Shraga Segal Department of Microbiology, Immunology, and Genetics, and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[{"name":"iUniversity of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Lumley","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Shi","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Tamms","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Feemster","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lupinacci","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwy","family":"Musey","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Bickham","sequence":"additional","affiliation":[{"name":"aMerck & Co., Inc., Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"V114-031 (PNEU-LINK) study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"9","key":"2023111414252705700_B1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJMoa1405870","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. children","volume":"372","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2023111414252705700_B2","doi-asserted-by":"crossref","first-page":"e0150949","DOI":"10.1371\/journal.pone.0150949","article-title":"Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: a systematic review","volume":"11","author":"Ngo","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"2023111414252705700_B3","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u20132015","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2023111414252705700_B4","unstructured":"Centers for Disease Control and Prevention\n . Pneumococcal disease surveillance and reporting. Available at: https:\/\/www.cdc.gov\/pneumococcal\/surveillance.html. Accessed March 1, 2022"},{"issue":"2","key":"2023111414252705700_B5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.vaccine.2014.11.011","article-title":"Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001\u20132012","volume":"33","author":"Lepoutre","year":"2015","journal-title":"Vaccine"},{"key":"2023111414252705700_B6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12879-016-1693-x","article-title":"Pneumonia hospitalizations in Scotland following the introduction of pneumococcal conjugate vaccination in young children","volume":"16","author":"Nair","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"9","key":"2023111414252705700_B7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2213-2600(14)70139-0","article-title":"Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomized trial","volume":"2","author":"Palmu","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"11","key":"2023111414252705700_B8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14760584.2019.1688149","article-title":"Serotype evolution in Western Europe: perspectives on invasive pneumococcal diseases (IPD)","volume":"18","author":"Tin Tin Htar","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"27","key":"2023111414252705700_B9","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1016\/j.vaccine.2014.03.065","article-title":"Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance","volume":"32","author":"Ben-Shimol","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"2023111414252705700_B10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"2023111414252705700_B11","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/cid\/cix115","article-title":"Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era","volume":"64","author":"Olarte","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"14","key":"2023111414252705700_B12","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jama.295.14.1668","article-title":"Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine","volume":"295","author":"Poehling","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"2023111414252705700_B13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1542\/peds.2009-1405","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine","volume":"125","author":"Bryant","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"2023111414252705700_B14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"issue":"3","key":"2023111414252705700_B15","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"2023111414252705700_B16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/13696998.2021.1970974","article-title":"Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines","volume":"24","author":"Hu","year":"2021","journal-title":"J Med Econ"},{"issue":"4","key":"2023111414252705700_B17","doi-asserted-by":"crossref","first-page":"512.e1","DOI":"10.1016\/j.cmi.2019.09.008","article-title":"Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the United States during 2017","volume":"26","author":"Varghese","year":"2020","journal-title":"Clinical Microbiology Infect"},{"issue":"44","key":"2023111414252705700_B18","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1016\/j.vaccine.2022.09.003","article-title":"A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)","volume":"40","author":"Banniettis","year":"2022","journal-title":"Vaccine"},{"issue":"3","key":"2023111414252705700_B19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2022.10.072","article-title":"A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)","volume":"41","author":"Bili","year":"2023","journal-title":"Vaccine"},{"issue":"5","key":"2023111414252705700_B20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.vaccine.2022.12.054","article-title":"A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)","volume":"41","author":"Lupinacci","year":"2023","journal-title":"Vaccine"},{"issue":"3","key":"2023111414252705700_B21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1182\/bloodadvances.2022008037","article-title":"Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with sickle cell disease (PNEU-SICKLE)","volume":"7","author":"Quinn","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2023111414252705700_B22","doi-asserted-by":"crossref","first-page":"e20190836","DOI":"10.1542\/peds.2019-0836","article-title":"Pneumococcal conjugate vaccine breakthrough infections: 2001\u20132016","volume":"145","author":"Adebanjo","year":"2020","journal-title":"Pediatrics"},{"issue":"4","key":"2023111414252705700_B23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/microorganisms9040738","article-title":"Serotype distribution of remaining pneumococcal meningitis in the mature PCV10\/13 period: findings from the PSERENADE project","volume":"9","author":"Garcia Quesada","year":"2021","journal-title":"Microorganisms"},{"issue":"7","key":"2023111414252705700_B24","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/cid\/cix418","article-title":"Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006\u20132014","volume":"65","author":"Oligbu","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2023111414252705700_B25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"issue":"8","key":"2023111414252705700_B26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/INF.0000000000002765","article-title":"A phase-II trial of safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants","volume":"39","author":"Platt","year":"2020","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-060428\/1566721\/peds_2022060428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-060428\/1566721\/peds_2022060428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:25:48Z","timestamp":1699971948000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/152\/1\/e2022060428\/191503\/Safety-and-Tolerability-of-V114-Pneumococcal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,6,13]]},"published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2022-060428","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"article-number":"e2022060428"}}